BACKGROUND: A growing trove of literature describes the effect of malnutrition and underweight on the incidence of inflammatory bowel disease (IBD). However, evidence regarding the association between underweight or obesity and IBD is limited. The study aimed to assess the association of body mass index (BMI) with a risk of IBD (Crohn's disease (CD) and ulcerative colitis (U.C.)) incidence. METHODS: We systematically searched PubMed/Medline, Cochrane, Web of Science, and Scopus for observational studies assessing the association between BMI and IBD that were published up to 30 June 2020. We estimated pooled hazard ratios (HR) with corresponding 95% confidence intervals (CI). Random effect dose-response meta-analysis was performed using the variance weighted least-squares regression (VWLS) models to identify non-linear associations. RESULTS: A total of ten studies involving 15.6 million individuals and 23,371 cases of IBD were included. Overall, obesity was associated with an increased IBD risk (HR: 1.20, 95% CI: 1.08-1.34, I 2 = 0%). Compared to normal weight, underweight (BMI < 18.5 kg/m2) and obesity (BMI ≥ 30 kg/m2) were associated with a higher risk of CD, and there was no difference in the risk of U.C. among those with BMI < 18.5 kg/m2 and BMI ≥ 30 kg/m2. There was a significant non-linear association between being underweight and obesity and the risk of development of CD (Coef1 = -0.0902, p 1 < 0.001 Coef2 = 0.0713, p 2 < 0.001). CONCLUSIONS: Obesity increases the risk of IBD development. Underweight and obesity are independently associated with an increased risk of CD, yet there is no evident association between BMI and the risk of U.C. Further studies are needed to clarify the underlying mechanism for these findings, particularly in CD.

Centre for Intelligent Healthcare Coventry University Coventry CV1 5FB UK

Department of Community Nutrition Faculty of Nutrition and Food Technology National Nutrition and Food Technology Research Institute Shahid Beheshti University of Medical Sciences Tehran 198396 3113 Iran

Department of Social and Clinical Pharmacy Faculty of Pharmacy Univerziti Kralova 500 03 Hradec Kralova Czech Republic

Division of Occupational Medicine Department of Medicine Faculty of Medicine University of Toronto Toronto ON M5G 2C4 Canada

Occupational Medicine Clinic St Michael's Hospital Unity Health Toronto Toronto ON M5C 2C5 Canada

Zobrazit více v PubMed

Abolhassani H., Alipour V. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol. 2020;5:17–30. PubMed PMC

Weimers P., Munkholm P. The natural history of IBD: Lessons learned. Curr. Teat. Options Gastroenterol. 2018;16:101–111. doi: 10.1007/s11938-018-0173-3. PubMed DOI

Pulley J., Todd A., Flatley C., Begun J. Malnutrition and quality of life among adult inflammatory bowel disease patients. JGH Open. 2020;4:454–460. doi: 10.1002/jgh3.12278. PubMed DOI PMC

Scaldaferri F., Pizzoferrato M., Lopetuso L.R., Musca T., Ingravalle F., Sicignano L.L., Mentella M., Miggiano G., Mele M.C., Gaetani E., et al. Nutrition and IBD: Malnutrition and/or sarcopenia? A practical guide. Gastroenterol. Res. Pract. 2017;2017:8646495. doi: 10.1155/2017/8646495. PubMed DOI PMC

Seminerio J.L., Koutroubakis I.E., Ramos-Rivers C., Hashash J.G., Dudekula A., Regueiro M., Baidoo L., Barrie A., Swoger J., Schwartz M., et al. Impact of obesity on the management and clinical course of patients with inflammatory bowel disease. Inflamm. Bowel Dis. 2015;21:2857–2863. doi: 10.1097/MIB.0000000000000560. PubMed DOI

Bryant R.V., Trott M.J., Bartholomeusz F.D., Andrews J.M. Systematic review: Body composition in adults with inflammatory bowel disease. Aliment. Pharmacol. Ther. 2013;38:213–225. doi: 10.1111/apt.12372. PubMed DOI

Steed H., Walsh S., Reynolds N. A brief report of the epidemiology of obesity in the inflammatory bowel disease population of Tayside, Scotland. Obes. Facts. 2009;2:370–372. doi: 10.1159/000262276. PubMed DOI PMC

Singh S., Khera R., Sandborn W.J. Obesity Is Associated with Worse Outcomes in Hospitalized Patients with Inflammatory Bowel Diseases: A Nationwide Analysis: 591. Am. J. Gastroenterol. 2016;111:S271. doi: 10.14309/00000434-201610001-00591. DOI

Mendall M.A., Jensen C.B., Sørensen T.I., Ängquist L.H., Jess T. Body mass index in young men and risk of inflammatory bowel disease through adult life: A population-based Danish cohort study. Sci. Rep. 2019;9:6360. doi: 10.1038/s41598-019-42642-8. PubMed DOI PMC

Jensen C.B., Ängquist L.H., Mendall M.A., Sørensen T.I., Baker J.L., Jess T. Childhood body mass index and risk of inflammatory bowel disease in adulthood: A population-based cohort study. Am. J. Gastroenterol. 2018;113:694–701. doi: 10.1038/s41395-018-0031-x. PubMed DOI

Mendall M., Harpsøe M.C., Kumar D., Andersson M., Jess T. Relation of body mass index to risk of developing inflammatory bowel disease amongst women in the Danish National Birth Cohort. PLoS ONE. 2018;13:e0190600. doi: 10.1371/journal.pone.0190600. PubMed DOI PMC

Khalili H., Ananthakrishnan A.N., Konijeti G.G., Higuchi L.M., Fuchs C.S., Richter J.M., Chan A.T. Measures of obesity and risk of Crohn’s disease and ulcerative colitis. Inflamm. Bowel Dis. 2015;21:361–368. doi: 10.1097/MIB.0000000000000283. PubMed DOI PMC

Harpsøe M.C., Basit S., Andersson M., Nielsen N.M., Frisch M., Wohlfahrt J., Nohr E.A., Linneberg A., Jess T. Body mass index and risk of autoimmune diseases: A study within the Danish National Birth Cohort. Int. J. Epidemiol. 2014;43:843–855. doi: 10.1093/ije/dyu045. PubMed DOI

Kuwahara E., Murakami Y., Nakamura T., Inoue N., Nagahori M., Matsui T., Watanabe M., Suzuki Y., Nishiwaki Y. Factors associated with exacerbation of newly diagnosed mild ulcerative colitis based on a nationwide registry in Japan. J. Gastroenterol. 2017;52:185–193. doi: 10.1007/s00535-016-1209-x. PubMed DOI

Chan S.S., Luben R., Olsen A., Tjonneland A., Kaaks R., Teucher B., Lindgren S., Grip O., Key T., Crowe F.L., et al. Body Mass Index and the Risk for Crohn’s Disease and Ulcerative Colitis: Data from a European Prospective Cohort Study (The IBD in EPIC Study) Am. J. Gastroenterol. 2013;108:575–582. doi: 10.1038/ajg.2012.453. PubMed DOI

Flores A., Burstein E., Cipher D.J., Feagins L.A. Obesity in inflammatory bowel disease: A marker of less severe disease. Dig. Dis. Sci. 2015;60:2436–2445. doi: 10.1007/s10620-015-3629-5. PubMed DOI

Melinder C., Hiyoshi A., Hussein O., Halfvarson J., Ekbom A., Montgomery S. Physical fitness in adolescence and subsequent inflammatory bowel disease risk. Clin. Transl. Gastroenterol. 2015;6:e121. doi: 10.1038/ctg.2015.49. PubMed DOI PMC

Dong J., Chen Y., Tang Y., Xu F., Yu C., Li Y., Pankaj P., Dai N. Body mass index is associated with inflammatory bowel disease: A systematic review and meta-analysis. PLoS ONE. 2015;10:e0144872. doi: 10.1371/journal.pone.0144872. PubMed DOI PMC

Rahmani J., Kord-Varkaneh H., Hekmatdoost A., Thompson J., Clark C., Salehisahlabadi A., Day A.S., Jacobson K. Body mass index and risk of inflammatory bowel disease: A systematic review and dose-response meta-analysis of cohort studies of over a million participants. Obes. Rev. 2019;20:1312–1320. doi: 10.1111/obr.12875. PubMed DOI

Moon J.M., Kang E.A., Han K., Hong S.W., Soh H., Park S., Lee J., Lee H.J., Im J.P., Kim J.S. Trends and risk factors of elderly-onset Crohn’s disease: A nationwide cohort study. World J. Gastroenterol. 2020;26:404–415. doi: 10.3748/wjg.v26.i4.404. PubMed DOI PMC

Liberati A., Altman D.G., Tetzlaff J., Mulrow C., Gøtzsche P.C., Ioannidis J.P., Clarke M., Devereaux P.J., Kleijnen J., Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. Br. Med. J. 2009;339:b2700. doi: 10.1136/bmj.b2700. PubMed DOI PMC

Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 2010;25:603–605. doi: 10.1007/s10654-010-9491-z. PubMed DOI

Jackson D., White I.R., Thompson S.G. Extending DerSimonian and Laird’s methodology to perform multivariate random effects meta-analyses. Stat. Med. 2010;29:1282–1297. doi: 10.1002/sim.3602. PubMed DOI

Orsini N., Li R., Wolk A., Khudyakov P., Spiegelman D. Meta-Analysis for linear and non-linear dose-response relations: Examples, an evaluation of approximations, and software. Am. J. Epidemiol. 2012;175:66–73. doi: 10.1093/aje/kwr265. PubMed DOI PMC

Singh S., Dulai P.S., Zarrinpar A., Ramamoorthy S., Sandborn W.J. Obesity in IBD: Epidemiology, pathogenesis, disease course and treatment outcomes. Nat. Rev. Gastroenterol. Hepatol. 2016;30:30. doi: 10.1038/nrgastro.2016.181. PubMed DOI PMC

Karmiris K., Koutroubakis I., Xidakis C., Polychronaki M., Voudouri T., Kouroumalis E.A. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm. Bowel Dis. 2006;12:100–105. doi: 10.1097/01.MIB.0000200345.38837.46. PubMed DOI

Peyrin-Biroulet L., Gonzales F., Dubuquoy L., Rousseaux C., Dubuquoy C., Decourcelle C., Saudemont A., Tachon M., Beclin E., Odou M.-F., et al. Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn’s disease. Gut. 2012;61:78–85. doi: 10.1136/gutjnl-2011-300370. PubMed DOI PMC

Konrad A., Lehrke M., Schachinger V., Seibold F., Stark R., Ochsenkuhn T., Parhofer K.G., Goke B., Broedl U.C. Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur. J. Gastroenterol. Hepatol. 2007;19:1070–1074. doi: 10.1097/MEG.0b013e3282f16251. PubMed DOI

Bilski J., Mazur-Bialy A., Wojcik D., Surmiak M., Magierowski M., Sliwowski Z., Pajdo R., Kwiecien S., Danielak A., Ptak-Belowska A., et al. Role of obesity, mesenteric adipose tissue, and adipokines in inflammatory bowel diseases. Biomolecules. 2019;9:780. doi: 10.3390/biom9120780. PubMed DOI PMC

Kim A. Dysbiosis: A review highlighting obesity and inflammatory bowel disease. J. Clin. Gastroenterol. 2015;49:S20–S24. doi: 10.1097/MCG.0000000000000356. PubMed DOI

Szilagyi A. Relationship(s) between obesity and inflammatory bowel diseases: Possible intertwined pathogenic mechanisms. Clin. J. Gastroenterol. 2020;13:139–152. doi: 10.1007/s12328-019-01037-y. PubMed DOI PMC

Spooren C.E., Wintjens D.S., de Jong M.J., van der Meulen-de A.E., Romberg-Camps M.J., Becx M.C., Maljaars J.P., van Bodegraven A.A., Mahmmod N., Markus T., et al. Risk of impaired nutritional status and flare occurrence in IBD outpatients. Dig. Liver Dis. 2019;51:1265–1269. doi: 10.1016/j.dld.2019.05.024. PubMed DOI

Ciocîrlan M., Ciocîrlan M., Iacob R., Tanțău A., Gheorghe L., Gheorghe C., Dobru D., Constantinescu G., Cijevschi C., Trifan A., et al. Malnutrition Prevalence in Newly Diagnosed Patients with Inflammatory Bowel Disease-Data from the National Romanian Database. J. Gastrointestin. Liver Dis. 2019;28:163–168. doi: 10.15403/jgld-176. PubMed DOI

Role of Adipose Tissue in Inflammatory Bowel Disease